Tesamorelin + Ipamorelin Blend 15mg Dosage & Mixing Guide

What is Tesamorelin + Ipamorelin Blend?

This is a pre-mixed vial holding two growth hormone peptides that were lyophilized together in a fixed 2:1 ratio:

The pairing is the classic GHRH-plus-secretagogue arrangement: two separate pituitary inputs rather than one, which in the broader class literature produces a larger GH pulse than either arm alone. Tesamorelin is the only FDA-approved GHRH analog (Egrifta, for HIV-associated lipodystrophy), and ipamorelin is the secretagogue with the cleanest published selectivity profile.

The thing that defines a pre-mixed vial: the ratio is locked in the powder. You cannot move one component without moving the other. Every draw is 2 parts tesamorelin to 1 part ipamorelin, whichever component you were actually aiming at. Researchers who want to titrate the two arms independently use separate vials instead.

Reconstitution

The blend reconstitutes with bacteriostatic water. Draw 2mL down the inside wall of the vial, swirl gently until both powders dissolve, and refrigerate. Do not shake. Both components dissolve readily and the finished solution should be clear and colourless.

Quick Reference

Reconstitution Guide

Materials Needed

• Tesamorelin + Ipamorelin Blend 15mg lyophilized vial
• Bacteriostatic water (BAC water)
• Insulin syringes (U-100, 29-31 gauge)
• Alcohol swabs
• Sharps container

Step-by-Step Instructions

1. Prepare workspace — Clean environment, gather materials, thorough handwashing.
2. Clean vial stoppers — Wipe both vials with alcohol swabs. Allow complete drying.
3. Draw BAC water — Draw 2mL bacteriostatic water using a sterile syringe.
4. Add to peptide — Inject slowly down the inside wall of the vial. Do not spray directly onto the powder.
5. Dissolve — Allow 2-5 minutes for complete dissolution. Gentle swirl only — no shaking.
6. Verify — Solution should be clear and colourless, with no visible particles.
7. Label and store — Note reconstitution date. Refrigerate immediately.

Dosage Protocol

Concentration Calculations

With 15mg total peptide in 2mL BAC water:

• Total concentration: 15mg / 2mL = 7.50mg/mL (7500mcg/mL)
• Tesamorelin: 10mg / 2mL = 5.00mg/mL (5000mcg/mL)
• Ipamorelin: 5mg / 2mL = 2.50mg/mL (2500mcg/mL)

Converting to U-100 syringe units (mg/mL x 1000 / 100):

• Total per unit: 7.50 x 1000 / 100 = 75mcg per unit
• Tesamorelin per unit: 5.00 x 1000 / 100 = 50mcg per unit
• Ipamorelin per unit: 2.50 x 1000 / 100 = 25mcg per unit

A convenient side effect of 2mL: the tesamorelin arm lands at exactly 5mg/mL, the same figure as the standalone tesamorelin 10mg vial reconstituted the same way. A tesamorelin-equivalent draw is the same number of units on both pages.

Run your exact vial and water combination through the peptide reconstitution calculator to rebuild these tables for your setup.

Common Dose Calculations

What a Tesamorelin-Target Draw Actually Delivers

Most researchers approach this vial with a tesamorelin number in mind, because tesamorelin is the component with an approved label to anchor to. Here is what rides along with it:

The label-equivalent 2mg tesamorelin draw carries 1000mcg of ipamorelin. That is roughly three to five times the 200-300mcg single-dose range used in most standalone ipamorelin work, and around ten times the ~100mcg per-administration saturation figure discussed in the secretagogue literature. Whether that matters depends on what you are measuring, but it is not the same protocol as running the two separately.

And the Reverse

Aiming at the ipamorelin arm instead pulls the tesamorelin dose well below label range:

A 300mcg ipamorelin draw gives 600mcg tesamorelin — under half the 1.4mg label dose. There is no draw volume that satisfies both a standard ipamorelin dose and a label-range tesamorelin dose at once. That is the whole trade-off of a fixed ratio, and it is worth sitting with before choosing a blend over two vials. The general arithmetic is walked through in peptide blend dosing maths.

Doses Per Vial

Research Considerations

Mechanism

The two components reach the somatotroph by different doors.

Tesamorelin is a stabilised GHRH(1-44) analog carrying a trans-3-hexenoyl group on the N-terminus, which slows DPP-4 degradation. It binds the GHRH receptor and drives pulsatile GH release in the physiological pattern. Its clinical dataset is the strongest of any peptide in this class: randomised trials in HIV-associated lipodystrophy showed significant visceral adipose tissue reduction with IGF-1 held inside normal range.

Ipamorelin is a pentapeptide agonist at GHS-R1a, the ghrelin receptor. What separates it from GHRP-2 and GHRP-6 is selectivity — the original Novo Nordisk characterisation reported GH release without the cortisol, prolactin and appetite signalling that the earlier GHRPs carry.

Because GHRH-receptor and GHS-receptor signalling converge on the same cell through different pathways, co-administration amplifies the GH pulse rather than simply adding to it. That synergy is well established for the drug classes — Bowers and colleagues demonstrated it in healthy men in 1990 — but it has not been tested for this specific fixed-ratio blend in any published human trial. Treat the combined behaviour as an extrapolation from class data, not a measured property of the vial.

Kinetics are worth noting too. Tesamorelin clears in roughly 8-13 minutes per the FDA label, with absolute subcutaneous bioavailability under 4%. Ipamorelin’s terminal half-life is about 2 hours in healthy volunteers (Gobburu et al., 1999). The GHRH signal is gone long before the secretagogue is, so the two arms are not present in the same proportion for the same length of time even though they went in together.

Sourcing for Research

Source from verified suppliers that provide third-party testing and certificates of analysis (COA) for each batch. For a blend, ask specifically whether the COA reports each component separately or only a combined purity figure — a single number cannot tell you whether the 2:1 ratio in the vial matches the ratio on the label. Compare purity documentation, shipping conditions, and batch traceability before purchasing research materials.

Storage Requirements

Lyophilized (Powder)

• Temperature: -20°C or colder
• Duration: 2+ years
• Conditions: Dry, dark, protected from moisture

Reconstituted

• Temperature: 2-8°C (refrigerated)
• Duration: 3-4 weeks
• Conditions: Protected from light, never freeze

Safety Considerations

• This blend is a research compound
• The fixed 2:1 combination is not approved for any indication in any jurisdiction
• Research use only — not for human consumption
• Use sterile technique; never reuse needles or syringes

Scientific References

1. Falutz J, et al. “Metabolic effects of a growth hormone-releasing factor in patients with HIV.” N Engl J Med. 2007;357(23):2359-2370.
2. EGRIFTA SV (tesamorelin for injection) prescribing information. U.S. Food and Drug Administration.
3. Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-561.
4. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. “Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.” Pharm Res. 1999;16(9):1412-1416.
5. Bowers CY, Reynolds GA, Durham D, et al. “Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.” J Clin Endocrinol Metab. 1990;70(4):975-982.

Last updated: 2026-07-21.

Disclaimer: This information is for educational and research purposes only. Tesamorelin + Ipamorelin Blend is a research compound combination and is not approved for any use. Research-grade peptides are not intended for human consumption. Always follow applicable laws and institutional guidelines.